
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is on track with its pipeline and a strong outlook for its clinical candidates in the endocrinology, immunology and inflammation, and metabolic disease areas. Its proprietary Native Complex Platform has shown promising activity in preclinical studies and is now being evaluated in a Phase 1 trial to evaluate the safety and tolerability of SEP-479 in healthy adult volunteers. Septerna's strong partnership with Novo Nordisk A/S provides additional financial support for its research and development efforts and its multiple discovery-stage programs have the potential to further expand its pipeline. Overall, Septerna's advancements and positive clinical data for its various candidates make it an attractive investment opportunity.
Bears say
Septerna is a clinical-stage biotechnology company that has yet to generate any significant revenue from its products or services. Despite its promising pipeline of product candidates, the company is still in the early stages of commercialization and faces significant competition in the endocrinology, immunology and inflammation, and metabolic disease markets. Additionally, its negative cash flow and high operating expenses suggest that the company may struggle to sustain itself in the long term without significant funding or successful product launches.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares